We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
TV.FIT is a streaming service and app that allows its users to access 100 hours of health & wellbeing content from global fitness experts & celebrities. Its subscription service is accessible in 66 countries across 6 continents. The platform aims to cater to all aspects of fitness, from mental health support for those who have yet to start to improve their fitness to creating content for those who are already working on their fitness regime. Its programs are created by some of the world’s most well-known fitness figures including George St-Pierre, Caroline Pearce, Gemma Atkinson, and Pierre Pozzuto. The platform has a global multimedia reach of over 8 million followers via partners such as TruFusion and CoolEvents, with another 6 million+ prospective users in the pipeline. TV.FIT also disseminates NHS-recommended mental-health-focused content on its platform. With the funds received, the platform aims to invest 31% of it in marketing, 28% in international content development, 22% in capital reserves, 18% in content production, and 1% towards repayment of debt.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £2,208,212
MysteryVibe creates doctor-recommended sexual health devices. The company combines research and engineering by onboarding leading doctors to design devices that address major sexual health issues such as erectile dysfunction, dryness and pain during intercourse. MysteryVibe has changed over 50,000 lives in 65 countries, witnessed $1 million worth of direct sales in 2020, and became the first sexual health startup to be featured on a BBC documentary. The company has received 20+ international awards including, the coveted Design Week Awards where its product, 'Crescendo', beat the Apple Watch. MysteryVibe has featured in media entities like Men's Health, Women's Health, The Daily Dot, and Forbes, to name a few. The company will use 25% of the investment to expand and scale its digital marketing campaign, 25% to launch two new products, 25% to expand its team, and 25% on building its inventory.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £498,020
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £655,011
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph